T1	Participants 112 139	HER2-positive breast cancer
T2	Participants 385 479	455 women with invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer
T3	Participants 870 889	Eighty-six patients
T4	Participants 1297 1317	86 enrolled patients
T5	Participants 2204 2340	patients with an increased likelihood of pCR after neoadjuvant trastuzumab, lapatinib, or their combination when given with chemotherapy
